p57Kip2 is an essential regulator of vitamin D receptor-dependent mechanisms

A cyclin-dependent kinase (CDK) inhibitor, p57Kip2, is an important molecule involved in bone development; p57Kip2-deficient (p57-/-) mice display neonatal lethality resulting from abnormal bone formation and cleft palate. The modulator 1α,25-dihydroxyvitamin D3 (l,25-(OH)2VD3) has shown the potential to suppress the proliferation and induce the differentiation of normal and tumor cells. The current study assessed the role of p57Kip2 in the 1,25-(OH)2VD3-regulated differentiation of osteoblasts because p57Kip2 is associated with the vitamin D receptor (VDR). Additionally, 1,25-(OH)2VD3 treatment increased p57KIP2 expression and induced the colocalization of p57KIP2 with VDR in the osteoblast nucleus. Primary p57-/- osteoblasts exhibited higher proliferation rates with Cdk activation than p57+/+ cells. A lower level of nodule mineralization was observed in p57-/- osteoblasts than in p57+/+ cells. In p57+/+ osteoblasts, 1,25-(OH)2VD3 upregulated the p57Kip2 and opn mRNA expression levels, while the opn expression levels were significantly decreased in p57-/- cells. The osteoclastogenesis assay performed using bone marrow cocultured with 1,25-(OH)2VD3-treated osteoblasts revealed a decreased efficiency of 1,25-(OH)2VD3-stimulated osteoclastogenesis in p57-/- cells. Based on these results, p57Kip2 might function as a mediator of 1,25-(OH)2VD3 signaling, thereby enabling sufficient VDR activation for osteoblast maturation.

[1]  Takashi Nakamura,et al.  VDR in Osteoblast‐Lineage Cells Primarily Mediates Vitamin D Treatment‐Induced Increase in Bone Mass by Suppressing Bone Resorption , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  N. Sharma-Walia,et al.  Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis , 2015, BMC Cancer.

[3]  J. Valdivielso,et al.  Lack of vitamin D receptor causes stress-induced premature senescence in vascular smooth muscle cells through enhanced local angiotensin-II signals. , 2014, Atherosclerosis.

[4]  D. Geerts,et al.  Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis , 2014, Cancer Medicine.

[5]  J. Pike,et al.  Genomic Determinants of Gene Regulation by 1,25-Dihydroxyvitamin D3 during Osteoblast-lineage Cell Differentiation*♦ , 2014, The Journal of Biological Chemistry.

[6]  P. Kaldis,et al.  p57(Kip2) regulates T-cell development and lymphoma. , 2014, Blood.

[7]  Makoto Sato,et al.  GPR98/Gpr98 gene is involved in the regulation of human and mouse bone mineral density. , 2012, The Journal of clinical endocrinology and metabolism.

[8]  S. Perrotta,et al.  p57Kip2 and Cancer: Time for a Critical Appraisal , 2011, Molecular Cancer Research.

[9]  E. Kavanagh,et al.  The hallmarks of CDKN1C (p57, KIP2) in cancer. , 2011, Biochimica et biophysica acta.

[10]  V. Gorgoulis,et al.  p57KIP2: “Kip”ing the Cell under Control , 2009, Molecular Cancer Research.

[11]  Y. Ouchi,et al.  TRIM44 interacts with and stabilizes terf, a TRIM ubiquitin E3 ligase. , 2009, Biochemical and biophysical research communications.

[12]  Keiji Tanaka,et al.  A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation , 2008, EMBO reports.

[13]  Y. Ouchi,et al.  Association of a single nucleotide polymorphism in the WISP1 gene with spinal osteoarthritis in postmenopausal Japanese women , 2007, Journal of Bone and Mineral Metabolism.

[14]  T. Martin,et al.  Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. , 2006, Cancer research.

[15]  B. Smedsrød,et al.  Osteoprotegerin is expressed in colon carcinoma cells. , 2005, Anticancer research.

[16]  R. Vessella,et al.  Osteoprotegerin in prostate cancer bone metastasis. , 2005, Cancer research.

[17]  B. De Moor,et al.  The Effects of 1α,25‐Dihydroxyvitamin D3 on the Expression of DNA Replication Genes , 2003 .

[18]  B. Joseph,et al.  p57Kip2 cooperates with Nurr1 in developing dopamine cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Nakayama,et al.  Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Kitazawa,et al.  Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter , 2003, Journal of cellular biochemistry.

[21]  T. Shinki,et al.  Vitamin D and bone , 2003, Journal of cellular biochemistry.

[22]  S. Kato,et al.  The function of nuclear receptors in bone tissues , 2003, Journal of Bone and Mineral Metabolism.

[23]  R. Kitazawa,et al.  Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. , 2002, Biochemical and biophysical research communications.

[24]  J. Eisman,et al.  Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. , 2001, The Journal of endocrinology.

[25]  K. Miyazono,et al.  Smad-mediated Transcription Is Required for Transforming Growth Factor-β1-induced p57Kip2 Proteolysis in Osteoblastic Cells* , 2001, The Journal of Biological Chemistry.

[26]  Silvia Bernardini,et al.  Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation , 2000, The Journal of cell biology.

[27]  Y. Ouchi,et al.  Possible involvement of the p57(Kip2) gene in bone metabolism. , 2000, Biochemical and biophysical research communications.

[28]  K. Nakayama,et al.  Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation. , 2000, Journal of biochemistry.

[29]  Y. Ouchi,et al.  p57Kip2 Is Degraded through the Proteasome in Osteoblasts Stimulated to Proliferation by Transforming Growth Factor β1* , 1999, The Journal of Biological Chemistry.

[30]  R. Kitazawa,et al.  Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. , 1999, Biochimica et biophysica acta.

[31]  M. Kumegawa,et al.  Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. , 1998, Biochemical and biophysical research communications.

[32]  L. Hofbauer,et al.  Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. , 1998, European journal of endocrinology.

[33]  K Yano,et al.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.

[34]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[36]  S. Elledge,et al.  Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome , 1997, Nature.

[37]  M. Barbacid,et al.  Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. , 1997, Genes & development.

[38]  M. Haussler,et al.  The vitamin D hormone and its nuclear receptor: molecular actions and disease states. , 1997, The Journal of endocrinology.

[39]  N. Koszewski,et al.  Vitamin D receptor interactions with the murine osteopontin response element , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[40]  G. Stein,et al.  Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. , 1996, Molecular endocrinology.

[41]  M. McKee,et al.  Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. , 1996, Connective tissue research.

[42]  J. Massagué,et al.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. , 1995, Genes & development.

[43]  S. Elledge,et al.  p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. , 1995, Genes & development.

[44]  S. van den Heuvel,et al.  Distinct roles for cyclin-dependent kinases in cell cycle control. , 1993, Science.

[45]  R. Weinberg,et al.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins , 1992, Cell.

[46]  G. Stein,et al.  Transcriptional control of vitamin D‐regulated proteins , 1992, Journal of cellular biochemistry.

[47]  H. DeLuca,et al.  Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[48]  H. DeLuca,et al.  Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. , 1979, The Journal of clinical investigation.